# Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)

> **NCT05594927** · PHASE3 · RECRUITING · sponsor: **Beijing Shenogen Biomedical Co., Ltd** · enrollment: 261 (estimated)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Icaritin
- **DRUG:** Huachansu

## Key facts

- **NCT ID:** NCT05594927
- **Lead sponsor:** Beijing Shenogen Biomedical Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-12-12
- **Primary completion:** 2025-08-30
- **Final completion:** 2025-08-30
- **Target enrollment:** 261 (ESTIMATED)
- **Last updated:** 2024-08-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05594927

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05594927, "Icaritin Soft Capsule Versus Huachansu Tablet in the First-line Treatment of Unresectable Hepatocellular Carcinoma With Poor Conditions and Biomarker Enrichment (Biomarker Enrichment Study of Poor Prognosis HCC Patients, BESTPOP)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05594927. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*